First-in-Human trial launches for new targeted cancer pill
NCT ID NCT06908434
Summary
This is the first study in people to test a new oral drug called GenSci128. It aims to see if the drug is safe and tolerable for patients with advanced solid tumors that have a specific genetic mutation called TP53 Y220C. The study will also look at how the drug moves through the body and gather early signs of whether it might help control the cancer.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for SOLID TUMORS HARBORING A TP53 Y220C MUTATION are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Zhongshan Hospital ,Fudan University
RECRUITINGShanghai, Shanghai Municipality, 200032, China
Contact Phone: •••-•••-••••
Contact
Conditions
Explore the condition pages connected to this study.